Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Alpha particle emitters in medicine

Conference ·
OSTI ID:6474792
Radiation-induced cancer of bone, liver and lung has been a prominent harmful side-effect of medical applications of alpha emitters. In recent years, however, the potential use of antibodies labeled with alpha emitting radionuclides against cancer has seemed promising because alpha particles are highly effective in cell killing. High dose rates at high LET, effectiveness under hypoxic conditions, and minimal expectancy of repair are additional advantages of alpha emitters over antibodies labeled with beta emitting radionuclides for cancer therapy. Cyclotron-produced astatine-211 ({sup 211}At) and natural bismuth-212 ({sup 212}Bi) have been proposed and are under extensive study in the United States and Europe. Radium-223 ({sup 223}Ra) also has favorable properties as a potential alpha emitting label, including a short-lived daughter chain with four alpha emissions. The radiation dosimetry of internal alpha emitters is complex due to nonuniformly distributed sources, short particle tracks, and high relative specific ionization. The variations in dose at the cellular level may be extreme. Alpha-particle radiation dosimetry, therefore, must involve analysis of statistical energy deposition probabilities for cellular level targets. It must also account fully for nonuniform distributions of sources in tissues, source-target geometries, and particle-track physics. 18 refs., 4 figs.
Research Organization:
Pacific Northwest Lab., Richland, WA (USA)
Sponsoring Organization:
DOE/NE
DOE Contract Number:
AC06-76RL01830
OSTI ID:
6474792
Report Number(s):
PNL-SA-17390; CONF-8909220--2; ON: DE91004761
Country of Publication:
United States
Language:
English

Similar Records

Microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy
Journal Article · Sat Oct 31 23:00:00 EST 1987 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5779909

Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Journal Article · Mon Sep 15 00:00:00 EDT 2008 · Current Radiopharmaceuticals, 1(3):127-134 · OSTI ID:949917

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Journal Article · Wed Feb 07 19:00:00 EST 2018 · Targeted Oncology · OSTI ID:1459839